- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02979925
Improving Functions in Veterans With Post-traumatic Peripheral Neuropathic Pain (PTP-NP)
Improving Functions in Veterans With Post-Traumatic Peripheral Neuropathic Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92161
- VA San Diego Healthcare System, San Diego, CA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
- Subject is willing and able to comply with scheduled visits, treatment plan, daily pain, sleep and all study related assessments and procedures
- Subjects must be literate in the language used in the assessments and pain diary
- Veterans (men or women) of any race or ethnicity who are at least 18 years of age
Female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 7 days after the last session of the assigned treatment
- A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active
Subject must have chronic peripheral neuropathic pain present for more than 4 months after a traumatic or surgical event per medical history, this may include, for example:
- motor vehicle accident
- fall
- sports injury
- knee or hip replacement
- hernia repair
- thoracotomy
- mastectomy
- focal/localized burns or crush injury
In addition, to be eligible for inclusion in the study, all subjects must:
- have an average daily Numerical Pain Rating Scale (NPRS) score >3 during B1; and
- have a spontaneous pain intensity >30 on 0-100 Mechanical Visual Analogue Scale (M-VAS) to be eligible for randomization
- Must have their implicated peripheral nerve(s) identified
- Must meet criteria for neuropathic pain assessment to meet eligibility for the study [46]. Pain distribution across a nerve territory and history indicates relevant lesion or disease plus criteria listed in a and/or b
(A): At least one negative or positive sensory sign or symptom confined to innervation territory of the lesioned nervous structure. Examples of negative or positive signs or symptoms include:
- Burning, stabbing or tingling sensation/pain
- Numbness/paresthesia
- Cold, heat or pressure
- Hyperalgesia or allodynia
- Hypoesthesia
- Increased or decreased sharp sensation (e.g., pinprick testing)
- Decreased vibration/vibratory sensation
- (B): Prior diagnostic tests confirming lesion or disease explaining neuropathic pain (Nerve conduction studies, EMG, skin or nerve biopsy). Documentation of affected nerve(s) indicating that the subject's pain is of neuropathic origin and is a result of injury/trauma to the affected/implicated nerve(s).
Exclusion Criteria:
Subjects presenting with ANY of the following will NOT be included in the study:
Subjects with neuropathic pain due to:
- diabetic peripheral neuropathy
- post herpetic neuralgia
- Human Immunodeficiency Virus
- chemo/anti-viral therapy
- trigeminal neuralgia
- carpal tunnel syndrome
- subjects whose post-traumatic neuropathic pain is categorized as central (e.g., spinal cord injury) rather than peripheral
- Subjects with pain due to Complex Regional Pain Syndrome (CRPS, Type I or Type II)
- Phantom limb pain after amputation. However, subjects with stump pain and phantom sensation but no phantom pain will not be excluded
- Subjects with skin conditions in the affected dermatome that in the judgment of the investigator can interfere with evaluation of the neuropathic pain condition
Subjects with other pain such as lumbar or cervical radiculopathy that may confound assessment or self-evaluation of the peripheral neuropathic pain
- subjects with significant somatic pain at the site of their trauma that may confound assessment or self-evaluation of their neuropathic pain
- Any subject considered at risk of suicide or self-harm based on investigator judgment and/or the details of a risk assessment
- Use of prohibited medications in the absence of appropriate washout periods
- Participation in any other clinical trial within the 30 days prior to screening and/or during participation in this study
- Subjects with a history of a cardiac arrhythmia that has led to the placement of a cardiac pacer or defibrillator will be excluded from the study
- Pregnant females and females of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception during the study
Subjects with a current diagnosis of DSM-IV-TR Axis I disorder, including, for example:
- schizophrenia
- bipolar disorder
- other psychotic disorders such as schizoaffective disorder and delusion disorder
- somatoform disorders or factitious disorders
- bipolar disorders, even if controlled or stable
- alcohol or substance related disorders in the past 2 years
- however, diagnoses of Generalized Anxiety Disorder (GAD) or major depression (MDD) that is clinically stable are allowed
Subjects with pending Worker's Compensation, Worker's Compensation, civil litigation or disability claims pertinent to the subject based upon trauma
- current involvement in out-of-court settlements for claims pertinent to subject's trauma
- subjects with fully resolved litigation and compensation claims can participate
- Subjects who have previously received either transcranial or transcutaneous magnetic stimulation therapy in the past
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active transcutaneous magnetic stimulation
Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
|
Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
Other Names:
|
Sham Comparator: Sham transcutaneous magnetic stimulation
Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
|
Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Spontaneous Pain Scores
Time Frame: Assessed during each of the subject's baseline visit, 1 week post treatment visit, and 4 weeks post treatment visit.
|
Spontaneous pain rating: Spontaneous pain level will be measured by using a sliding algometer, known as the Mechanical Visual Analog Scale (M-VAS).
The device has been well validated, and is anchored at the left by "no pain sensation" and at the right by "the most intense pain sensation imaginable."
The corresponding length of the red bar with a scale from 0 to 100, which can be read on the back by the tester, represents the subject's intensity of pain.
0 represents "no pain sensation" and 100 represents "the most intense pain sensation imaginable."
A lower value indicates a better outcome with lower levels of pain reported.
|
Assessed during each of the subject's baseline visit, 1 week post treatment visit, and 4 weeks post treatment visit.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Evoked Pain Scores: Stroking
Time Frame: Assessed during each of the subject's baseline visit, 1 week post treatment visit, and 4 weeks post treatment visit.
|
Stroking evoked pain will be assessed by gently moving a paintbrush over the site of PTNP.
The patients will be asked if pain is felt.
If so, the intensity of pain will be rated on a scale known as the Mechanical Visual Analog Scale (M-VAS).
The device has been well validated, and is anchored at the left by "no pain sensation" and at the right by "the most intense pain sensation imaginable."
The corresponding length of the red bar with a scale from 0 to 100, which can be read on the back by the tester, represents the subject's intensity of pain.
0 represents "no pain sensation" and 100 represents "the most intense pain sensation imaginable."
A lower value indicates a better outcome with lower levels of pain reported.
|
Assessed during each of the subject's baseline visit, 1 week post treatment visit, and 4 weeks post treatment visit.
|
Evaluation of Evoked Pain Scores: Von Frey
Time Frame: Assessed during each of the subject's baseline visit, 1 week post treatment visit, and 4 weeks post treatment visit.
|
Punctate evoked pain will be conducted by gently pressing a 5.18 von Frey monofilament against the site of PTNP.
The patients will be asked if pain is felt.
If so, the intensity of pain will be rated on a scale known as the Mechanical Visual Analog Scale (M-VAS).
The device has been well validated, and is anchored at the left by "no pain sensation" and at the right by "the most intense pain sensation imaginable."
The corresponding length of the red bar with a scale from 0 to 100, which can be read on the back by the tester, represents the subject's intensity of pain.
0 represents "no pain sensation" and 100 represents "the most intense pain sensation imaginable."
A lower value indicates a better outcome with lower levels of pain reported.
|
Assessed during each of the subject's baseline visit, 1 week post treatment visit, and 4 weeks post treatment visit.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Albert Yick Leung, MD, VA San Diego Healthcare System, San Diego, CA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B2366-P
- 1192133 (Other Grant/Funding Number: VA San Diego Healthcare System)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathic Pain
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Hospices Civils de LyonCompletedPharmacoresistant Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedNeuropathic Pain RebelFrance
-
University Hospital, Strasbourg, FranceTerminatedPostthoracotomy Pain | Postthoracoscopy Neuropathic PainFrance
-
AstraZenecaCompletedNociceptive Pain | Peripheral Neuropathic PainUnited Kingdom
-
Ashwin ViswanathanBoston Scientific CorporationNot yet recruitingChronic Pain | Neuropathic Pain | Pain, NeuropathicUnited States
Clinical Trials on Active Transcutaneous Magnetic Stimulation
-
ZyGood LLCUniversity of Maryland; Kaiser PermanenteUnknownDiabetic Peripheral Neuropathy
-
University of Sao Paulo General HospitalRecruiting
-
Burrell College of Osteopathic MedicineRecruitingPsoriasis VulgarisUnited States
-
Hawra Al-DandanRecruitingOveractive Bladder SyndromeSaudi Arabia
-
University of AarhusCompletedUrinary Incontinence | Enuresis | Nocturnal EnuresisDenmark
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruitingParkinson DiseaseChina
-
University of CincinnatiLindner Center of HOPE; Brain & Behavior Research FoundationCompletedMajor Depressive DisorderUnited States
-
Queen Mary University of LondonKing's College LondonWithdrawn
-
University of California, Los AngelesRecruiting
-
General and Teaching Hospital CeljeRecruitingCritical Illness MyopathySlovenia